INNOVATE Corp. Third Quarter 2026 Earnings Conference Call - INNOVATE CORP

Financial Performance:

• Consolidated revenue for Q3 2026 reached $495.5 million, a 42.8% year-over-year increase driven by the Infrastructure segment.
• Net income was $15.8 million ($1.10 per diluted share), a turnaround from a $9.4 million net loss ($0.71 per share) in the prior year period.
• Adjusted EBITDA totaled $40.5 million, up from $19.8 million year-over-year, primarily fueled by Infrastructure performance.
• Infrastructure revenue rose 45% to $490.6 million, while Infrastructure EBITDA increased to $43.6 million from $23.5 million.
• Life Sciences revenue declined 61.3% to $1.2 million due to lower unit sales at R2; Life Sciences adjusted EBITDA loss improved due to lower compensation costs despite lower gross profit.
• Spectrum revenue was $3.7 million (down from $5.6 million) as the segment only consolidated two months of results prior to the sale of controlling interest.
• Total principal indebtedness was $583.3 million as of September 30, 2026; subsequent to quarter-end, net proceeds from the DBMG sale ($413 million) were used to fully repay the corporate credit line and redeem $325 million of senior secured notes, reducing total debt to $238.3 million.
• Cash and cash equivalents stood at $4.9 million as of September 30, 2026.
• Reported backlog was $2.6 billion and adjusted backlog was $1.7 billion as of September 30, 2026.

Guidance and Future Outlook:

• Management aims to convert the strong commercial pipeline into broader utilization for MetaBeacon and R2 over the coming quarters.
• MetaBeacon anticipates initial use of its transdermal GFR technology in Big Pharma clinical trials starting in 2027.
• R2 expects 60 systems currently in production to be delivered by November 30, with manufacturing capacity expansion underway to meet demand.
• The company intends to further reduce debt ($238.3 million current level) by monetizing remaining assets and maintaining a disciplined capital allocation approach.
• Long-term focus remains on unlocking value from the simplified portfolio, specifically the growth potential of MetaBeacon and R2.

Business Segments and Product Lines:

• Infrastructure: DBM Global (the primary component) delivered strong margins with gross margin improving 170 bps to 15.3% and adjusted EBITDA margin improving 200 bps to 8.9%. The segment closed with a healthy backlog of $2.7 billion.
• Life Sciences:
  • MetaBeacon: The TGFR system was nominated for the 2026 "Prick Scallion" award. The company secured orders for 600 monitors in China (shipments Q4 2026–Q2 2027) and advanced reimbursement coding discussions with CMS and private payers. FDA approval for Investigational Device Exemption on a third-generation wireless sensor was obtained.
  • R2: Worldwide demand reached 3.1 million units with 1.2 million recognized as revenue; 116 systems ($1.9 million future revenue) exited the quarter.
• Spectrum: Completed the sale of a controlling interest to ConnexCorp while retaining a 25% stake (with an option to acquire up to 40%). The segment now has 287 operating stations and 80% ownership of Genoval (orthopedics).
• Divestitures: DBM Global was sold to IES Holdings on October 5, 2026, crystallizing value and providing liquidity.

Market and Competitive Landscape:

• Infrastructure demand remains healthy, driven by investments in computing, AI, advanced manufacturing, semiconductors, energy, and digital connectivity.
• Key activity markets for DBM Global include Technology, Healthcare, and New York City.
• MetaBeacon's technology is gaining traction in preclinical research among Big Pharma and clinical centers, positioning it as a potential standard for kidney function assessment.
• R2 faces strong underlying global demand, requiring rapid scaling of manufacturing capabilities.

Risks and Challenges:

• Implementation/Conversion Risk: Management noted that conversion timing for new technology adoption (e.g., MetaBeacon's TGFR system) can take six to 12 months.
• Margin Fluctuations: Infrastructure margins faced pressure from higher SG&A and material cost fluctuations in the industrial maintenance segment, partially offset by core steel fabrication gains.
• Revenue Decline: Life Sciences segment experienced significant revenue drops due to lower unit sales at R2.
• Regulatory/Reimbursement: Success relies on advancing reimbursement coding and regulatory approvals for new wireless sensor systems.

Management Commentary and Tone:

• Management tone was confident and optimistic, highlighting "exceptional performance" and "significant progress" in portfolio simplification.
• Leadership expressed pride in DBM Global's exit and strategic positioning of the remaining assets for future growth.
• The tone emphasized discipline in capital allocation and a sharp focus on maximizing the value of remaining assets.
• No analyst questions were raised during the Q&A session, allowing for a standard closing statement.

Analyst Questions and Answers:

• The Q&A session was closed with no questions from the floor.
• Closing remarks from CEO Paul Voigt reiterated the strategic progress made and the company's focus on growth and value creation.

Other Key Points:

• Potential Milestone Payments: Innovate holds a 75% economic interest in Pantheon, which owns 76% of Benevir (sold to J&J); Innovate is eligible for up to $500 million in aggregate milestone payments ($250M development, $650M commercial).
• Genoval: Innovate holds an 80% interest in Genoval, a device company developing knee replacement technologies for osteoarthritis.
• Debt Structure: The sale of DBM Global allowed for the full repayment of DBMG's $68.7 million debt and a significant reduction in corporate-level debt.
• Accounting Changes: Spectrum results now utilize the equity method following the reduction of ownership to a non-controlling 25% stake.